LYRA Company Profile and Key Details

Q: Who are the executives of LYRA?

Dr. Harlan W. Waksal M.D.Executive ChairmanDr. Maria Palasis Ph.D.Chief Executive Officer, Pres & DirectorMr. R. Donald Elsey MBAAdvisorDr. Robert Richard Ph.D.Senior Vice President of Technical OperationsMs. Ellen CavaleriSenior Vice President of Investor Relations & CommunicationsMr. Ray KnoxVice President of OperationsMs. Vineeta Belanger Ph.D.Senior Vice President of Clinical AffairsDr. Richard Nieman M.D.Chief Medical OfficerMs. Corinne NoyesSenior Vice President of Commercial Strategy & Market Devel.Dr. Carmichael S. Roberts Jr., Ph.D.Co-FounderDr. John E. Bishop Ph.D.Chief Technology OfficerMr. Jason CavalierChief Financial Officer, Treasurer & Sec.

NASDAQ : LYRA

Lyra Therapeutics

$0.50

At Close 4:00 PM

60.05

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Lyra Therapeutics, Inc. (LYRA) stock remained unchanged at $0.50 a share on NASDAQ. The stock opened at $1.29, fluctuating between $0.49 to $1.33 during the session.

Stock Snapshot

0.495

Prev. Close

878.57K

Market Cap

0.4893

Day Low

-0.02

P/E Ratio

-22.9

EPS (TTM)

-1.12

Cash Flow per Share

1.29

Open

1.77M

Number of Shares

1.3269

Day High

76.33%

Free Float in %

1.56

Book Value

1.04M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 16, 2026	1.29	1.33	0.48	0.50	1.02M
Mar 13, 2026	1.32	1.34	1.32	1.32	3.22K
Mar 12, 2026	1.31	1.35	1.30	1.34	8.22K
Mar 11, 2026	1.30	1.42	1.27	1.31	16.62K
Mar 10, 2026	1.28	1.32	1.24	1.30	13.61K
Mar 09, 2026	1.29	1.30	1.23	1.30	9.28K
Mar 06, 2026	1.28	1.30	1.25	1.28	14.71K
Mar 03, 2026	1.18	1.27	1.08	1.24	83.37K
Mar 02, 2026	0.97	1.45	0.91	1.19	695.63K
Feb 27, 2026	1.13	1.19	1.00	1.01	82.75K
Feb 26, 2026	1.37	1.46	1.12	1.12	122.33K
Feb 25, 2026	1.46	1.48	1.40	1.40	5.96K
Feb 24, 2026	1.44	1.47	1.39	1.46	22.88K
Feb 23, 2026	1.46	1.46	1.43	1.45	5.26K
Feb 20, 2026	1.49	1.51	1.45	1.45	12.57K
Feb 19, 2026	1.42	1.52	1.41	1.49	14.94K
Feb 18, 2026	1.29	1.48	1.29	1.40	17.2K
Feb 17, 2026	1.42	1.45	1.28	1.35	23.87K
Feb 13, 2026	1.35	1.45	1.21	1.39	80.74K
Feb 12, 2026	1.39	1.40	1.32	1.32	29.39K

Contact Details

Watertown, MA 02472

United States

https://lyratherapeutics.com 617 393 4600

About Company

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Stock Peers

REGN

-14.93-1.97%

Regeneron Pharmaceuticals, Inc.$744.12 ARGX

-21.26-3.01%

argenx SE$684.77 UTHR

-9.67-1.79%

United Therapeutics Corporation$530.35 VRTX

-10.9-2.36%

Vertex Pharmaceuticals Incorporated$451.59 MDGL

-1.18-0.27%

Madrigal Pharmaceuticals, Inc.$442.00 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.62-1.75%

Alnylam Pharmaceuticals, Inc.$314.80 PRAX

-14.59-4.81%

Praxis Precision Medicines, Inc.$288.79 KRYS

-5.5-2.15%

Krystal Biotech, Inc.$250.83 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

The stock is currently within 5% of its 52-week low $0.48 and $37.50. With a market capitalization of about $878.57 thousand, Lyra Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.06). Key stats such as the average daily volume over the past year has been around 105.24 thousand shares, trading with heavier-than-usual volume. Headquartered in Watertown, MA, Lyra Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carmichael S. Roberts Jr., the company employs approximately 30 people and listed since May 01, 2020. Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis.

Technical Performance

LYRA has shown mixed momentum, gaining 13.59% over the past week and -66.1% over the past quarter, though year-to-date performance is down -24.03%. Short-term trend indicators are bullishly aligned (SMA20 -28.84%, SMA50 -53.23%, SMA200 -81.86%). The stock’s 14-day RSI is 28.56 (weak momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.01% below its high and over -7.66% above its low. Average 10-day trading volume of 178.68 thousand shares is significantly above the 3-month average of 100.45 thousand, indicating heightened recent market interest.

Valuation Metrics

Lyra Therapeutics, Inc. trades at a P/E ratio of -0.03, slightly below the S&P 500 average, with a price-to-sales ratio of 1.46 and a price-to-book ratio of -0.2 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.03, also below market averages.

Dividend & Fair Value

Lyra Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.16. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Lyra Therapeutics, Inc. generated EPS of -$23.78 over the past year. Five-year average earnings growth is -2.22%. The latest quarter delivered EPS of -$3.38. The next quarter is forecast at $nan. Next year's EPS is expected at $16.94. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $16.00. The high target offers 3165.31% upside. The low target suggests 3165.31% downside. The mean target is $16.00. This offers 3165.31% upside. Lyra Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -19.21%. The prior quarter beat by -4.84%. Over the last six quarters, Apple has recorded several small beats. These include -14.71% in August 14, 2024.

Shareholding & Insider Activity

Lyra Therapeutics, Inc. has 1.64 million shares outstanding. The public float is 1.12 million shares, elevated short interest at 3.66% of float. This equals 50.50 thousand shares. The short ratio is 1.68 days. Institutional investors hold 38.39% of the float. Insiders own 0.67%. EDELMAN JOSEPH holds 7.86 million shares, North Bridge Venture Management VI, L.P. has 1.32 million shares and Palasis Maria has 1.10 million shares. Over the past six months, insider transactions show net selling. They sold 14.21 thousand shares across 8 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Lyra Therapeutics generated $1.56M in revenue, or $0.03 per share. Gross margin was 82.16%, operating margin -4205.91%, and net profit margin -4023.11%. Returns are negative, with ROA at -43.96% and ROE at -70.10%.
On valuation metrics, Lyra Therapeutics trades at a P/E of -0.03, P/S of 1.46 and P/B of -0.20. The current ratio is 2.43 and quick ratio is 2.43. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -762.85 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -7.25, supported by a cash flow-to-debt ratio of -1.09.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Lyra Therapeutics posted revenue of $1.56M, down slightly from $1.36M in the prior quarter. Gross profit was $1.28M (margin 82.16%). Operating income was - $65.53M (margin -4205.9%). Net income was- $62.68M (EPS - $1.26).
The company ended the quarter with $102.75M in cash and short-term investments, a total debt of $26.88M, and net debt of $4.53M. Total assets were $142.60M, with equity of $89.42M. Financials further reflected weakness, with operating cash flow of - $63.30M, free cash flow of - $64.35M, and capital expenditures of - $1.05M.

Price Forecast & Outlook

Our AI price prediction model suggests that Lyra Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 21.21%, with price expected at $0.60 by March 30, 2026, within a range of $0.38 to $0.85 3-Month Outlook: Projected fall of -61.62%, reaching $0.19 by June 12, 2026, with a range of $0.00 to $0.53. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 16, 2027, within a range of $0.00 to $11.56.

Key Takeaways

Lyra Therapeutics, Inc. (NASDAQ:LYRA) shares are down -24.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Lyra Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.03. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $10.29, suggesting 1978.79% upside. Our AI forecast model points to short-term strength (21.21% over two weeks), a medium-term fall (-61.62% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Lyra Therapeutics, Inc. (LYRA) stock price?

Lyra Therapeutics, Inc. (NASDAQ: LYRA) stock price is $0.50 in the last trading session. During the trading session, LYRA stock reached the peak price of $1.33 while $0.49 was the lowest point it dropped to. The percentage change in LYRA stock occurred in the recent session was 0% while the dollar amount for the price change in LYRA stock was $0.00.

LYRA's industry and sector of operation?

The NASDAQ listed LYRA is part of Biotechnology industry that operates in the broader Healthcare sector. Lyra Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LYRA?

Dr. Harlan W. Waksal M.D.
Executive Chairman
Dr. Maria Palasis Ph.D.
Chief Executive Officer, Pres & Director
Mr. R. Donald Elsey MBA
Advisor
Dr. Robert Richard Ph.D.
Senior Vice President of Technical Operations
Ms. Ellen Cavaleri
Senior Vice President of Investor Relations & Communications
Mr. Ray Knox
Vice President of Operations
Ms. Vineeta Belanger Ph.D.
Senior Vice President of Clinical Affairs
Dr. Richard Nieman M.D.
Chief Medical Officer
Ms. Corinne Noyes
Senior Vice President of Commercial Strategy & Market Devel.
Dr. Carmichael S. Roberts Jr., Ph.D.
Co-Founder
Dr. John E. Bishop Ph.D.
Chief Technology Officer
Mr. Jason Cavalier
Chief Financial Officer, Treasurer & Sec.

How LYRA did perform over past 52-week?

LYRA's closing price is 2.06% higher than its 52-week low of $0.49 where as its distance from 52-week high of $37.50 is -98.68%.

How many employees does LYRA have?

Number of LYRA employees currently stands at 30.

Link for LYRA official website?

Official Website of LYRA is: https://lyratherapeutics.com

How do I contact LYRA?

LYRA could be contacted at phone 617 393 4600 and can also be accessed through its website. LYRA operates from 480 Arsenal Way, Watertown, MA 02472, United States.

How many shares of LYRA are traded daily?

LYRA stock volume for the day was 1.04M shares. The average number of LYRA shares traded daily for last 3 months was 105.24K.

What is the market cap of LYRA currently?

The market value of LYRA currently stands at $878.57K with its latest stock price at $0.50 and 1.77M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	30
Beta	0.06
Sales or Revenue	$1.56M
5Y Sales Change%	-0.842%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

LYRA Company Profile and Key Details

Lyra Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics